Memantine ER/Donepezil: Difference between revisions

Line 4:

| classes = Combined cholinesterase inhibitor + NMDA antagonist

| uses = <vote slug="alzheimers-use">Moderate-to-severe Alzheimer's dementia</vote>

| starting_dose = For patients already stable on memantine 28 mg/d + donepezil 10 mg/d — switch to one capsule daily of equivalent strength

| starting_dose = For patients already stable on memantine 28 mg/d + donepezil 10 mg/d, switch to one capsule daily of equivalent strength

| preparations = 7/10, 14/10, 21/10, 28/10 mg ER capsules (memantine ER / donepezil)

| fda_max = 28/10 mg/d

Line 14:

| pregnancy = Not relevant (geriatric problem)

| legal = Rx-only in US

| mechanism = Donepezil: reversible AChE inhibitor — increases synaptic acetylcholine. Memantine: uncompetitive low-affinity NMDA receptor antagonist — dampens pathological glutamate overactivation while preserving normal synaptic signaling. Targets two distinct mechanisms in Alzheimer's.

| mechanism = Donepezil: reversible AChE inhibitor, increases synaptic acetylcholine. Memantine: uncompetitive low-affinity NMDA receptor antagonist, dampens pathological glutamate overactivation while preserving normal synaptic signaling. Targets two distinct mechanisms in Alzheimer's.

| intro = Namzaric is a once-daily fixed-dose combination of memantine ER and donepezil, for patients with moderate-to-severe Alzheimer's already stable on both components. The convenience is real — daily pill burden cut roughly in half. The trade-off is reduced ability to titrate each component independently.

| intro = Namzaric is a once-daily fixed-dose combination of memantine ER and donepezil, for patients with moderate-to-severe Alzheimer's already stable on both components. The convenience is real, daily pill burden cut roughly in half. The trade-off is reduced ability to titrate each component independently.

| indications =

| dosing =

MDElliottMD (talk | contribs)